Using the A-DAC principle to unlock new treatment options in Hodgkin lymphoma
On the 23rd of October, 2016 a panel of hematological oncology experts gathered for a satellite symposium on ‘The Evolution of Chemotherapy: using the A-DAC principle to unlock new treatment options in Hodgkin lymphoma’, during the 10th International Symposium on Hodgkin Lymphoma in Cologne, Germany.
The symposium, sponsored by Mundipharma-EDO, featured recent developments in a new concept for using chemotherapy and DNA damage repair in the treatment of hematological malignancies that is hoped to overcome resistance. This included pre-clinical data from the first-in-human clinical trial of the new fusion molecule EDO-S101, which is currently being trialled for treatment of relapsed/refractory hematological malignancies. EDO-S101 is the first drug to represent the ‘A-DAC principle’, a new approach to standard chemotherapy ,which combines an alkylating agent with a pan-histone deacetylase inhibitor (HDAC) to simultaneously damage DNA and block damage repair.
Chaired by Dr Volker Diehl, the symposium covers the evolution of chemotherapy, the challenges of resistance and the latest, exciting developments in EDO-S101 research.
All educational videos in this feature were supported by a grant from Mundipharma EDO to Magdalen Medical Publishing and were recorded at the 10th International Symposium on Hodgkin Lymphoma 2016.
Chair, Volker Diehl, MD, PhD, from the University of Cologne, Germany, makes the opening remarks to the symposium on the evolution of chemotherapy, using the A-DAC principle to unlock new treatment options in Hodgkin lymphoma, and introduces the panel of experts. Dr Diehl describes the exciting new principle as the fusion of “two fighters” into one molecule, with the hope of increasing treatment efficacy whilst lowering toxicity.
Volker Diehl, MD, PhD, from the University of Cologne, Germany, provides an overview of how chemotherapy has evolved over time, specifically for the treatment of Hodgkin lymphoma. Dr Diehl explains the challenges of chemotherapy, including toxicity and resistance, and discusses current treatment regiments.
Antonello Pinto, MD, from the National Cancer Institute, Naples, Italy, presents the latest pre-clinical data on the fusion molecule EDO-S101 in Hodgkin lymphoma. EDO-S101 is based on the A-DAC principle and has the potential to meet the current clinical needs in Hodgkin lymphoma patients, and patients with other relapsed/refractory hematological malignancies.
Christoph Driessen, MD from Kantonsspital St. Gallen, Switzerland, presents the latest pre-clinical data for EDO-S101 in multiple myeloma, and the early results of the Phase I clinical trial that is currently ongoing in Hodgkin lymphoma.
Volker Diehl, MD, PhD from the University of Cologne, Germany, explains the rationale behind the A-DAC principle, by presenting two patient case studies from the ongoing EDO-S101 Phase I study. Dr Diehl then opens the floor for the Q&A session.